Jennifer A. Pietenpol

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation · 2011 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Definition of a consensus binding site for p53

Wafik S. El‐Deiry, Scott E. Kern, Jennifer A. Pietenpol et al. · Nature Genetics · 1992 · 2K citations

Life Sciences, Molecular Biology, Molecular Genetics +10

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Jonathan D. Oliner, Jennifer A. Pietenpol, Sam Thiagalingam et al. · Nature · 1993 · 1.5K citations

Medicine, Cancer Biology, Oncology +16

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Brian D. Lehmann, Bojana Jovanović, Xi Chen et al. · PLoS ONE · 2016 · 1.4K citations · Full text

Medicine, Cancer Biology, Oncology +17

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

Hiroko Masuda, Keith Baggerly, Ying Wang et al. · Clinical Cancer Research · 2013 · 733 citations · Full text

Medicine, Cancer Biology, Oncology +17